Cereblon isoform 4
Magnetospirillum gryphiswaldense MSR-1
当前结构中的状态
| Assembly | 聚集状态 | 构建体 | 突变与修饰 | 配体、离子与共同组分 | 实验方法与环境 | 结构质量 |
|---|---|---|---|---|---|---|
| 1 | 蛋白单体 单体 蛋白 × 1 PDB 声明:monomeric(1) 与蛋白拷贝数一致 | 链 A; UniProt 1–124 | 未记录 | ZN ZINC ION × 1 JP5 (phenylmethyl) ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamate × 1 | X-RAY DIFFRACTION X-ray结晶条件:VAPOR DIFFUSION, SITTING DROP;294 K;15 % PEG 6K, 5 % Glycerol | 分辨率 1.10 Å R-free 0.150 |
| 2 | 蛋白单体 单体 蛋白 × 1 PDB 声明:monomeric(1) 与蛋白拷贝数一致 | 链 B; UniProt 1–124 | 未记录 | ZN ZINC ION × 1 JP5 (phenylmethyl) ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamate × 1 | X-RAY DIFFRACTION X-ray结晶条件:VAPOR DIFFUSION, SITTING DROP;294 K;15 % PEG 6K, 5 % Glycerol | 分辨率 1.10 Å R-free 0.150 |
数据库中的同蛋白其他状态
以下每一行都是同一 UniProt 蛋白在另一个 PDB 条目中的 biological assembly, “相对当前条目”直接指出证据层面的不同;没有差异标签表示当前已读取字段一致。
| 其他 PDB | 相对当前条目 6R1D | Assembly / 聚集状态 | 构建体 | 突变与修饰 | 配体、离子与非聚合物 | 实验方法与环境 | 结构质量 |
|---|---|---|---|---|---|---|---|
| 4V2Y Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide 提交 2014-10-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
0.1 M MAGNESIUM CHLORIDE, 0.1 M SODIUM CITRATE PH 5, 15%(W/V) PEG 4000
|
分辨率 1.40 Å R-free 0.195 |
| 4V2Y Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide 提交 2014-10-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
0.1 M MAGNESIUM CHLORIDE, 0.1 M SODIUM CITRATE PH 5, 15%(W/V) PEG 4000
|
分辨率 1.40 Å R-free 0.195 |
| 4V2Y Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide 提交 2014-10-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
0.1 M MAGNESIUM CHLORIDE, 0.1 M SODIUM CITRATE PH 5, 15%(W/V) PEG 4000
|
分辨率 1.40 Å R-free 0.195 |
| 4V2Z Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Pomalidomide 提交 2014-10-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 Y70 S-Pomalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
0.1 M SODIUM ACETATE PH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.45 Å R-free 0.203 |
| 4V2Z Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Pomalidomide 提交 2014-10-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 Y70 S-Pomalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
0.1 M SODIUM ACETATE PH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.45 Å R-free 0.203 |
| 4V2Z Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Pomalidomide 提交 2014-10-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 Y70 S-Pomalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
0.1 M SODIUM ACETATE PH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.45 Å R-free 0.203 |
| 4V30 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Lenalidomide 提交 2014-10-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 LVY S-Lenalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
15 %(W/V) PEG 6000, 5 %(W/V) GLYCEROL
|
分辨率 1.85 Å R-free 0.239 |
| 4V30 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Lenalidomide 提交 2014-10-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 LVY S-Lenalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
15 %(W/V) PEG 6000, 5 %(W/V) GLYCEROL
|
分辨率 1.85 Å R-free 0.239 |
| 4V30 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Lenalidomide 提交 2014-10-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 LVY S-Lenalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
15 %(W/V) PEG 6000, 5 %(W/V) GLYCEROL
|
分辨率 1.85 Å R-free 0.239 |
| 4V31 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Deoxyuridine 提交 2014-10-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 DUR 2'-DEOXYURIDINE × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
0.1 M CITRIC ACID PH 3.5, 25 %(W/V) PEG 3350
|
分辨率 1.80 Å R-free 0.219 |
| 4V31 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Deoxyuridine 提交 2014-10-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 DUR 2'-DEOXYURIDINE × 1 FLC CITRATE ANION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
0.1 M CITRIC ACID PH 3.5, 25 %(W/V) PEG 3350
|
分辨率 1.80 Å R-free 0.219 |
| 4V31 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Deoxyuridine 提交 2014-10-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 DUR 2'-DEOXYURIDINE × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
0.1 M CITRIC ACID PH 3.5, 25 %(W/V) PEG 3350
|
分辨率 1.80 Å R-free 0.219 |
| 4V32 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Y101F mutant 提交 2014-10-15 | 突变/修饰不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
突变:YES | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
0.2 M SODIUM CHLORIDE, 0.1 M PHOSPHATE-CITRATE PH 4.2, 20 %(W/V) PEG 8000
|
分辨率 1.90 Å R-free 0.240 |
| 4V32 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Y101F mutant 提交 2014-10-15 | 突变/修饰不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
突变:YES | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
0.2 M SODIUM CHLORIDE, 0.1 M PHOSPHATE-CITRATE PH 4.2, 20 %(W/V) PEG 8000
|
分辨率 1.90 Å R-free 0.240 |
| 4V32 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Y101F mutant 提交 2014-10-15 | 突变/修饰不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
突变:YES | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
0.2 M SODIUM CHLORIDE, 0.1 M PHOSPHATE-CITRATE PH 4.2, 20 %(W/V) PEG 8000
|
分辨率 1.90 Å R-free 0.240 |
| 5AMH Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, trigonal crystal form 提交 2015-03-10 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 CA CALCIUM ION × 1 CL CHLORIDE ION × 7 NI NICKEL (II) ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
100 MM SODIUM ACETATE PH 4.6, 2.2 M CALCIUM CHLORIDE
|
分辨率 1.20 Å R-free 0.157 |
| 5AMI Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Wash I structure 提交 2015-03-10 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
100 MM SODIUM ACETATE PH 4.6, 20 %(W/V) PEG 6000
|
分辨率 1.75 Å R-free 0.209 |
| 5AMI Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Wash I structure 提交 2015-03-10 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
100 MM SODIUM ACETATE PH 4.6, 20 %(W/V) PEG 6000
|
分辨率 1.75 Å R-free 0.209 |
| 5AMI Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Wash I structure 提交 2015-03-10 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
100 MM SODIUM ACETATE PH 4.6, 20 %(W/V) PEG 6000
|
分辨率 1.75 Å R-free 0.209 |
| 5AMJ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Wash II structure 提交 2015-03-10 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 2 |
X-RAY DIFFRACTION
X-ray结晶条件
100 MM TRI-SODIUM CITRATE PH 5.6, 1.0 M AMMONIUM PHOSPHATE
|
分辨率 1.75 Å R-free 0.191 |
| 5AMJ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Wash II structure 提交 2015-03-10 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 2 |
X-RAY DIFFRACTION
X-ray结晶条件
100 MM TRI-SODIUM CITRATE PH 5.6, 1.0 M AMMONIUM PHOSPHATE
|
分辨率 1.75 Å R-free 0.191 |
| 5AMJ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Wash II structure 提交 2015-03-10 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
100 MM TRI-SODIUM CITRATE PH 5.6, 1.0 M AMMONIUM PHOSPHATE
|
分辨率 1.75 Å R-free 0.191 |
| 5AMK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in multiple conformations, hexagonal crystal form 提交 2015-03-10 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
64 MM SODIUM CITRATE PH 7.0, 100 MM HEPES PH 7.0, 10 %(W/V) PEG 5000 MME
|
分辨率 2.90 Å R-free 0.217 |
| 5AMK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in multiple conformations, hexagonal crystal form 提交 2015-03-10 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
64 MM SODIUM CITRATE PH 7.0, 100 MM HEPES PH 7.0, 10 %(W/V) PEG 5000 MME
|
分辨率 2.90 Å R-free 0.217 |
| 5AMK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in multiple conformations, hexagonal crystal form 提交 2015-03-10 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 DMS DIMETHYL SULFOXIDE × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
64 MM SODIUM CITRATE PH 7.0, 100 MM HEPES PH 7.0, 10 %(W/V) PEG 5000 MME
|
分辨率 2.90 Å R-free 0.217 |
| 5AMK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in multiple conformations, hexagonal crystal form 提交 2015-03-10 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 4 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 D
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
64 MM SODIUM CITRATE PH 7.0, 100 MM HEPES PH 7.0, 10 %(W/V) PEG 5000 MME
|
分辨率 2.90 Å R-free 0.217 |
| 5OH1 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Aminoglutethimide 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate PH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.70 Å R-free 0.210 |
| 5OH1 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Aminoglutethimide 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate PH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.70 Å R-free 0.210 |
| 5OH1 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Aminoglutethimide 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 9UQ (3~{R})-3-(4-aminophenyl)-3-ethyl-piperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate PH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.70 Å R-free 0.210 |
| 5OH2 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Pyrrolidin-2-one (Butyrolactam) 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 BAQ pyrrolidin-2-one × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.90 Å R-free 0.225 |
| 5OH2 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Pyrrolidin-2-one (Butyrolactam) 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 BAQ pyrrolidin-2-one × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.90 Å R-free 0.225 |
| 5OH2 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Pyrrolidin-2-one (Butyrolactam) 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 BAQ pyrrolidin-2-one × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.90 Å R-free 0.225 |
| 5OH3 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Ethosuximide 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 9V2 (3~{S})-3-ethyl-3-methyl-pyrrolidine-2,5-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 2.10 Å R-free 0.231 |
| 5OH3 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Ethosuximide 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 9V2 (3~{S})-3-ethyl-3-methyl-pyrrolidine-2,5-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 2.10 Å R-free 0.231 |
| 5OH3 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Ethosuximide 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 2.10 Å R-free 0.231 |
| 5OH4 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Piperidine-2,6-dione (Glutarimide) 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 9UZ piperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 2.30 Å R-free 0.250 |
| 5OH4 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Piperidine-2,6-dione (Glutarimide) 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 9UZ piperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 2.30 Å R-free 0.250 |
| 5OH4 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Piperidine-2,6-dione (Glutarimide) 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 9UZ piperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 2.30 Å R-free 0.250 |
| 5OH7 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Imidazolidine-2,4-dione (Hydantoin) 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 HYN imidazolidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.85 Å R-free 0.203 |
| 5OH7 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Imidazolidine-2,4-dione (Hydantoin) 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 HYN imidazolidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.85 Å R-free 0.203 |
| 5OH7 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Imidazolidine-2,4-dione (Hydantoin) 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.85 Å R-free 0.203 |
| 5OH8 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Rolipram 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 ROL ROLIPRAM × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.95 Å R-free 0.220 |
| 5OH8 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Rolipram 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 ROL ROLIPRAM × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.95 Å R-free 0.220 |
| 5OH8 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Rolipram 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.95 Å R-free 0.220 |
| 5OH9 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thiazolidine-2,4-dione 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 OD3 1,3-thiazolidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.65 Å R-free 0.210 |
| 5OH9 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thiazolidine-2,4-dione 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 OD3 1,3-thiazolidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.65 Å R-free 0.210 |
| 5OH9 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thiazolidine-2,4-dione 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 OD3 1,3-thiazolidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.65 Å R-free 0.210 |
| 5OHA Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with 2-Thiohydantoin 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 9UW 2-sulfanylideneimidazol-4-one × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.55 Å R-free 0.197 |
| 5OHA Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with 2-Thiohydantoin 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 9UW 2-sulfanylideneimidazol-4-one × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.55 Å R-free 0.197 |
| 5OHA Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with 2-Thiohydantoin 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 9UW 2-sulfanylideneimidazol-4-one × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.55 Å R-free 0.197 |
| 5OHB Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Piperidin-2-one (Valerolactam) 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 V1L piperidin-2-one × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.70 Å R-free 0.212 |
| 5OHB Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Piperidin-2-one (Valerolactam) 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 V1L piperidin-2-one × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.70 Å R-free 0.212 |
| 5OHB Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Piperidin-2-one (Valerolactam) 提交 2017-07-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 V1L piperidin-2-one × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
|
分辨率 1.70 Å R-free 0.212 |
| 6R0Q Mutant cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with thalidomide metabolite alpha-(o-carboxybenzamido)glutarimide 提交 2019-03-13 | 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric |
链 A
1–124(124 aa)
|
突变:A52H, M54Y, F56H, R68N, A72R, I87V, L89Q | ZN ZINC ION × 1 JNW 2-[[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]carbamoyl]benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;20 % PEG 3350, 0.2 M Ammonium acetate
|
分辨率 1.50 Å R-free 0.190 |
| 6R0Q Mutant cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with thalidomide metabolite alpha-(o-carboxybenzamido)glutarimide 提交 2019-03-13 | 突变/修饰不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
突变:A52H, M54Y, F56H, R68N, A72R, I87V, L89Q | ZN ZINC ION × 1 JNW 2-[[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]carbamoyl]benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;20 % PEG 3350, 0.2 M Ammonium acetate
|
分辨率 1.50 Å R-free 0.190 |
| 6R0Q Mutant cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with thalidomide metabolite alpha-(o-carboxybenzamido)glutarimide 提交 2019-03-13 | 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric |
链 C
1–124(124 aa)
|
突变:A52H, M54Y, F56H, R68N, A72R, I87V, L89Q | ZN ZINC ION × 1 JNW 2-[[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]carbamoyl]benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;20 % PEG 3350, 0.2 M Ammonium acetate
|
分辨率 1.50 Å R-free 0.190 |
| 6R0Q Mutant cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with thalidomide metabolite alpha-(o-carboxybenzamido)glutarimide 提交 2019-03-13 | 突变/修饰不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 4 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 D
1–124(124 aa)
|
突变:A52H, M54Y, F56H, R68N, A72R, I87V, L89Q | ZN ZINC ION × 1 JNW 2-[[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]carbamoyl]benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;20 % PEG 3350, 0.2 M Ammonium acetate
|
分辨率 1.50 Å R-free 0.190 |
| 6R0S Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 4a and hydrolysis product 提交 2019-03-13 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.55 Å R-free 0.213 |
| 6R0S Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 4a and hydrolysis product 提交 2019-03-13 | 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 PO4 PHOSPHATE ION × 1 JOE 2-[[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamoyl]-6-nitro-benzoic acid × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.55 Å R-free 0.213 |
| 6R0S Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 4a and hydrolysis product 提交 2019-03-13 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 JOH 2-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]-4-nitro-isoindole-1,3-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.55 Å R-free 0.213 |
| 6R0U Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 5a and hydrolysis product 提交 2019-03-13 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.70 Å R-free 0.227 |
| 6R0U Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 5a and hydrolysis product 提交 2019-03-13 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 PO4 PHOSPHATE ION × 1 CL CHLORIDE ION × 1 JO8 3-azanyl-2-[[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamoyl]benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.70 Å R-free 0.227 |
| 6R0U Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 5a and hydrolysis product 提交 2019-03-13 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 PO4 PHOSPHATE ION × 1 JO5 4-azanyl-2-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]isoindole-1,3-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.70 Å R-free 0.227 |
| 6R0V Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with hydrolysis product of compound 4b 提交 2019-03-13 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 JO2 2-[[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamoyl]-4-nitro-benzoic acid × 1 PO4 PHOSPHATE ION × 3 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.60 Å R-free 0.219 |
| 6R0V Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with hydrolysis product of compound 4b 提交 2019-03-13 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 JO2 2-[[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamoyl]-4-nitro-benzoic acid × 1 PO4 PHOSPHATE ION × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.60 Å R-free 0.219 |
| 6R0V Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with hydrolysis product of compound 4b 提交 2019-03-13 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 JO2 2-[[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamoyl]-4-nitro-benzoic acid × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.60 Å R-free 0.219 |
| 6R11 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 5b 提交 2019-03-13 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 JOB 5-azanyl-2-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]isoindole-1,3-dione × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium Phosphate
|
分辨率 1.75 Å R-free 0.227 |
| 6R11 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 5b 提交 2019-03-13 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 JOB 5-azanyl-2-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]isoindole-1,3-dione × 1 PO4 PHOSPHATE ION × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium Phosphate
|
分辨率 1.75 Å R-free 0.227 |
| 6R11 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 5b 提交 2019-03-13 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium Phosphate
|
分辨率 1.75 Å R-free 0.227 |
| 6R12 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7b 提交 2019-03-13 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.74 Å R-free 0.234 |
| 6R12 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7b 提交 2019-03-13 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 PO4 PHOSPHATE ION × 1 JOT ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]-2-phenyl-ethanamide × 1 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.74 Å R-free 0.234 |
| 6R12 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7b 提交 2019-03-13 | 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.74 Å R-free 0.234 |
| 6R13 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7f 提交 2019-03-13 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.65 Å R-free 0.224 |
| 6R13 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7f 提交 2019-03-13 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 PO4 PHOSPHATE ION × 1 JOK ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]-3-phenyl-propanamide × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.65 Å R-free 0.224 |
| 6R13 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7f 提交 2019-03-13 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.65 Å R-free 0.224 |
| 6R18 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 11a 提交 2019-03-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.35 Å R-free 0.197 |
| 6R18 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 11a 提交 2019-03-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 PO4 PHOSPHATE ION × 1 JOQ [4-(aminomethyl)phenyl]methyl ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamate × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.35 Å R-free 0.197 |
| 6R18 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 11a 提交 2019-03-14 | 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.35 Å R-free 0.197 |
| 6R19 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20a 提交 2019-03-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.45 Å R-free 0.201 |
| 6R19 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20a 提交 2019-03-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 PO4 PHOSPHATE ION × 2 JON [(2~{S})-pyrrolidin-2-yl]methyl ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamate × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.45 Å R-free 0.201 |
| 6R19 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20a 提交 2019-03-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.45 Å R-free 0.201 |
| 6R1A Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20b 提交 2019-03-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 m Ammonium phosphate
|
分辨率 1.54 Å R-free 0.208 |
| 6R1A Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20b 提交 2019-03-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 2 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 m Ammonium phosphate
|
分辨率 1.54 Å R-free 0.208 |
| 6R1A Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20b 提交 2019-03-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 PO4 PHOSPHATE ION × 1 JP8 [(2~{R})-pyrrolidin-2-yl]methyl ~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]carbamate × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 m Ammonium phosphate
|
分辨率 1.54 Å R-free 0.208 |
| 6R1C Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 12a 提交 2019-03-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ASP ASPARTIC ACID × 1 ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.50 Å R-free 0.215 |
| 6R1C Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 12a 提交 2019-03-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 PO4 PHOSPHATE ION × 2 JOW 4-[[4-[[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamoyloxymethyl]phenyl]methylamino]-4-oxidanylidene-butanoic acid × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.50 Å R-free 0.215 |
| 6R1C Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 12a 提交 2019-03-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.50 Å R-free 0.215 |
| 6R1K Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7c 提交 2019-03-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 JPB ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]-2,4,6-tris(chloranyl)benzamide × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.94 Å R-free 0.212 |
| 6R1K Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7c 提交 2019-03-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 JPB ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]-2,4,6-tris(chloranyl)benzamide × 2 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.94 Å R-free 0.212 |
| 6R1K Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7c 提交 2019-03-14 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 JPB ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]-2,4,6-tris(chloranyl)benzamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.94 Å R-free 0.212 |
| 6R1W Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 16b 提交 2019-03-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium Phosphate
|
分辨率 1.35 Å R-free 0.198 |
| 6R1W Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 16b 提交 2019-03-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 PO4 PHOSPHATE ION × 2 JPW (4-azanylcyclohexyl)methyl ~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]carbamate × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium Phosphate
|
分辨率 1.35 Å R-free 0.198 |
| 6R1W Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 16b 提交 2019-03-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 PO4 PHOSPHATE ION × 1 JPW (4-azanylcyclohexyl)methyl ~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]carbamate × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium Phosphate
|
分辨率 1.35 Å R-free 0.198 |
| 6R1X Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7a 提交 2019-03-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 JPQ ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]-3-methyl-but-2-enamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.80 Å R-free 0.216 |
| 6R1X Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7a 提交 2019-03-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 JPQ ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]-3-methyl-but-2-enamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.80 Å R-free 0.216 |
| 6R1X Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7a 提交 2019-03-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
|
分辨率 1.80 Å R-free 0.216 |
| 7PJK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with a benzotriazole analog of thalidomide 提交 2021-08-24 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 7SE (3S)-3-(benzotriazol-2-yl)piperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;293 K;0.4 M (NH4)2HPO4
|
分辨率 1.99 Å R-free 0.254 |
| 7PJK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with a benzotriazole analog of thalidomide 提交 2021-08-24 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 7SE (3S)-3-(benzotriazol-2-yl)piperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;293 K;0.4 M (NH4)2HPO4
|
分辨率 1.99 Å R-free 0.254 |
| 7PJK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with a benzotriazole analog of thalidomide 提交 2021-08-24 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;293 K;0.4 M (NH4)2HPO4
|
分辨率 1.99 Å R-free 0.254 |
| 7PS9 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Iberdomide (CC-220) 提交 2021-09-22 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 8W7 (3S)-3-[4-({4-[(morpholin-4-yl)methyl]phenyl}methoxy)-1-oxo-1,3-dihydro-2H-isoindol-2-yl]piperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;293 K;0.5 M (NH4)H2PO4
|
分辨率 1.80 Å R-free 0.246 |
| 7PS9 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Iberdomide (CC-220) 提交 2021-09-22 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 8W7 (3S)-3-[4-({4-[(morpholin-4-yl)methyl]phenyl}methoxy)-1-oxo-1,3-dihydro-2H-isoindol-2-yl]piperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;293 K;0.5 M (NH4)H2PO4
|
分辨率 1.80 Å R-free 0.246 |
| 7PS9 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Iberdomide (CC-220) 提交 2021-09-22 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 8W7 (3S)-3-[4-({4-[(morpholin-4-yl)methyl]phenyl}methoxy)-1-oxo-1,3-dihydro-2H-isoindol-2-yl]piperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;293 K;0.5 M (NH4)H2PO4
|
分辨率 1.80 Å R-free 0.246 |
| 7PSO Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Avadomide (CC-122) 提交 2021-09-23 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;293 K;0.5 M (NH4)H2PO4
|
分辨率 1.52 Å R-free 0.217 |
| 7PSO Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Avadomide (CC-122) 提交 2021-09-23 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;293 K;0.5 M (NH4)H2PO4
|
分辨率 1.52 Å R-free 0.217 |
| 7PSO Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Avadomide (CC-122) 提交 2021-09-23 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 PO4 PHOSPHATE ION × 1 835 (3S)-3-(5-azanyl-2-methyl-4-oxidanylidene-quinazolin-3-yl)piperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;293 K;0.5 M (NH4)H2PO4
|
分辨率 1.52 Å R-free 0.217 |
| 7SHH Bacterial cereblon homologue in complex with (R)-3-(4-methoxyphenyl)piperidine-2,6-dione 提交 2021-10-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 9FT (3R)-3-(4-methoxyphenyl)piperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 4.6;291 K;0. 1M sodium acetate and 16% PEG 6000
|
分辨率 1.90 Å R-free 0.216 |
| 7SHH Bacterial cereblon homologue in complex with (R)-3-(4-methoxyphenyl)piperidine-2,6-dione 提交 2021-10-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 9FT (3R)-3-(4-methoxyphenyl)piperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 4.6;291 K;0. 1M sodium acetate and 16% PEG 6000
|
分辨率 1.90 Å R-free 0.216 |
| 7SHH Bacterial cereblon homologue in complex with (R)-3-(4-methoxyphenyl)piperidine-2,6-dione 提交 2021-10-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 9FT (3R)-3-(4-methoxyphenyl)piperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 4.6;291 K;0. 1M sodium acetate and 16% PEG 6000
|
分辨率 1.90 Å R-free 0.216 |
| 8AOP Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 14r 提交 2022-08-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 MW6 (3S)-3-[(3-aminophenyl)sulfanylmethyl]piperidine-2,6-dione × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.4M Ammonium Phosphate
|
分辨率 1.94 Å R-free 0.227 |
| 8AOP Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 14r 提交 2022-08-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 MW6 (3S)-3-[(3-aminophenyl)sulfanylmethyl]piperidine-2,6-dione × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.4M Ammonium Phosphate
|
分辨率 1.94 Å R-free 0.227 |
| 8AOP Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 14r 提交 2022-08-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.4M Ammonium Phosphate
|
分辨率 1.94 Å R-free 0.227 |
| 8AOQ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20a 提交 2022-08-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 N8F (3~{S})-3-(phenylsulfonylmethyl)piperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.4M Ammonium Phosphate
|
分辨率 2.09 Å R-free 0.233 |
| 8AOQ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20a 提交 2022-08-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 N8F (3~{S})-3-(phenylsulfonylmethyl)piperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.4M Ammonium Phosphate
|
分辨率 2.09 Å R-free 0.233 |
| 8AOQ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20a 提交 2022-08-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;294 K;0.4M Ammonium Phosphate
|
分辨率 2.09 Å R-free 0.233 |
| 8BC6 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex an aspartimide degron peptide 提交 2022-10-15 | 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 PO4 PHOSPHATE ION × 3 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.5 M (NH4)H2PO4
|
分辨率 1.72 Å R-free 0.223 |
| 8BC6 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex an aspartimide degron peptide 提交 2022-10-15 | 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 PO4 PHOSPHATE ION × 2 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.5 M (NH4)H2PO4
|
分辨率 1.72 Å R-free 0.223 |
| 8BC6 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex an aspartimide degron peptide 提交 2022-10-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.5 M (NH4)H2PO4
|
分辨率 1.72 Å R-free 0.223 |
| 8BC7 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex an aminoglutarimide degron peptide 提交 2022-10-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.5 M (NH4)H2PO4
|
分辨率 1.72 Å R-free 0.211 |
| 8BC7 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex an aminoglutarimide degron peptide 提交 2022-10-15 | 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.5 M (NH4)H2PO4
|
分辨率 1.72 Å R-free 0.211 |
| 8BC7 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex an aminoglutarimide degron peptide 提交 2022-10-15 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 EF2 S-Thalidomide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;294 K;0.5 M (NH4)H2PO4
|
分辨率 1.72 Å R-free 0.211 |
| 8C3H Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex a long aspartimide degron peptide 提交 2022-12-23 | 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION;274 K;0.5 M (NH4)H2PO4
|
分辨率 1.71 Å R-free 0.210 |
| 8C3H Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex a long aspartimide degron peptide 提交 2022-12-23 | 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION;274 K;0.5 M (NH4)H2PO4
|
分辨率 1.71 Å R-free 0.210 |
| 8C3H Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex a long aspartimide degron peptide 提交 2022-12-23 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION;274 K;0.5 M (NH4)H2PO4
|
分辨率 1.71 Å R-free 0.210 |
| 8OU3 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 8d 提交 2023-04-21 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 3 PDB 声明:trimeric |
链 A
1–124(124 aa)
链 B
1–124(124 aa)
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 3 EF2 S-Thalidomide × 2 PO4 PHOSPHATE ION × 3 W1T 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2-fluoranyl-benzamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
|
分辨率 1.47 Å R-free 0.238 |
| 8OU4 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11a 提交 2023-04-21 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 W2F 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2-chloranyl-benzamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
|
分辨率 2.25 Å R-free 0.269 |
| 8OU4 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11a 提交 2023-04-21 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 W2F 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2-chloranyl-benzamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
|
分辨率 2.25 Å R-free 0.269 |
| 8OU4 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11a 提交 2023-04-21 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
|
分辨率 2.25 Å R-free 0.269 |
| 8OU5 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11b 提交 2023-04-21 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 3 PDB 声明:trimeric |
链 A
1–124(124 aa)
链 B
1–124(124 aa)
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 3 W1X 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2-(trifluoromethyl)benzamide × 2 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
|
分辨率 2.30 Å R-free 0.253 |
| 8OU6 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11c 提交 2023-04-21 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 3 PDB 声明:trimeric |
链 A
20–123(104 aa)
链 B
20–123(104 aa)
链 C
20–123(104 aa)
|
未记录 | ZN ZINC ION × 3 W26 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2-methyl-benzamide × 2 PO4 PHOSPHATE ION × 4 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
|
分辨率 1.84 Å R-free 0.225 |
| 8OU7 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11d 提交 2023-04-22 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 W1F 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2-methoxy-benzamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
|
分辨率 1.70 Å R-free 0.224 |
| 8OU7 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11d 提交 2023-04-22 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 W1F 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2-methoxy-benzamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
|
分辨率 1.70 Å R-free 0.224 |
| 8OU7 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11d 提交 2023-04-22 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 W1F 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2-methoxy-benzamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
|
分辨率 1.70 Å R-free 0.224 |
| 8OU9 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11e 提交 2023-04-22 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 3 PDB 声明:trimeric |
链 A
18–123(106 aa)
链 B
18–123(106 aa)
链 C
18–123(106 aa)
|
未记录 | ZN ZINC ION × 3 W1B 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2-oxidanyl-benzamide × 3 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
|
分辨率 1.75 Å R-free 0.224 |
| 8OUA Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11f 提交 2023-04-22 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 3 PDB 声明:trimeric |
链 A
19–123(105 aa)
链 B
19–123(105 aa)
链 C
18–123(106 aa)
|
未记录 | ZN ZINC ION × 3 W0Z 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2,5-bis(fluoranyl)-3-methoxy-benzamide × 2 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
|
分辨率 1.85 Å R-free 0.238 |
| 8RDP Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8a 提交 2023-12-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1HZ7 (5~{S})-3-(2-chlorophenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
|
分辨率 1.76 Å R-free 0.230 |
| 8RDP Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8a 提交 2023-12-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1HZ7 (5~{S})-3-(2-chlorophenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
|
分辨率 1.76 Å R-free 0.230 |
| 8RDP Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8a 提交 2023-12-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1HZ7 (5~{S})-3-(2-chlorophenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
|
分辨率 1.76 Å R-free 0.230 |
| 8RDQ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8b 提交 2023-12-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 YQO (5S)-3-(2,4-dichlorophenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 2.03 Å R-free 0.249 |
| 8RDQ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8b 提交 2023-12-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 YQO (5S)-3-(2,4-dichlorophenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 2.03 Å R-free 0.249 |
| 8RDQ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8b 提交 2023-12-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 2.03 Å R-free 0.249 |
| 8RDR Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8g 提交 2023-12-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1HZ3 (5~{S})-3-(2-nitrophenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 1.58 Å R-free 0.214 |
| 8RDR Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8g 提交 2023-12-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1HZ3 (5~{S})-3-(2-nitrophenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 1.58 Å R-free 0.214 |
| 8RDR Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8g 提交 2023-12-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1HZ3 (5~{S})-3-(2-nitrophenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 1.58 Å R-free 0.214 |
| 8RDS Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8i 提交 2023-12-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1HZ6 (5~{S})-3-(2-methoxyphenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 2.00 Å R-free 0.253 |
| 8RDS Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8i 提交 2023-12-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1HZ6 (5~{S})-3-(2-methoxyphenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 2.00 Å R-free 0.253 |
| 8RDS Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8i 提交 2023-12-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 2.00 Å R-free 0.253 |
| 8RDT Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8j 提交 2023-12-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1HZ2 (5~{S})-3-(2,3,4-trimethoxyphenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM Thalidomide
|
分辨率 1.95 Å R-free 0.242 |
| 8RDT Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8j 提交 2023-12-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1HZ2 (5~{S})-3-(2,3,4-trimethoxyphenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM Thalidomide
|
分辨率 1.95 Å R-free 0.242 |
| 8RDT Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8j 提交 2023-12-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM Thalidomide
|
分辨率 1.95 Å R-free 0.242 |
| 9GJQ Crystal structure of humanised cereblon from Magnetospirillum gryphiswaldense bound by dihydrouracil-indole compound [1-(1H-indol-6-yl)dihydro-2,4(1H,3H)-pyrimidinedione]. 提交 2024-08-22 | 构建体不同 突变/修饰不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
18–124(107 aa)
|
突变:A52H, M54Y, F56H, F77H, Y101F, R117A | A1IMN 1-(1H-indol-6-yl)-1,3-diazinane-2,4-dione × 1 ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;293 K;10 % PEG8000, 8 % ethylene glycol and 100 mM Na-HEPES buffer (pH 7.5)
|
分辨率 1.39 Å R-free 0.209 |
| 9HTK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2n 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1IXA (3S)-3-phenylsulfanylpiperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 1.49 Å R-free 0.210 |
| 9HTK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2n 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1I4R (3R)-3-phenylsulfanylpiperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 1.49 Å R-free 0.210 |
| 9HTK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2n 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1IXA (3S)-3-phenylsulfanylpiperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 1.49 Å R-free 0.210 |
| 9HTL Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2j 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1IW9 (3~{R})-3-phenoxypiperidine-2,6-dione × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 1.74 Å R-free 0.217 |
| 9HTL Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2j 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1IW9 (3~{R})-3-phenoxypiperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 1.74 Å R-free 0.217 |
| 9HTL Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2j 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 1.74 Å R-free 0.217 |
| 9HTM Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2o 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1IW8 (3R)-3-phenylazanylpiperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 1.85 Å R-free 0.237 |
| 9HTM Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2o 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1IW8 (3R)-3-phenylazanylpiperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 1.85 Å R-free 0.237 |
| 9HTM Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2o 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1I4P (3S)-3-phenylazanylpiperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 1.85 Å R-free 0.237 |
| 9HTN Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2s 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1IW7 (3R)-3-(3,4-dihydro-2H-quinolin-1-yl)piperidine-2,6-dione × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
|
分辨率 1.92 Å R-free 0.235 |
| 9HTN Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2s 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1I4Q (3S)-3-(3,4-dihydro-2H-quinolin-1-yl)piperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
|
分辨率 1.92 Å R-free 0.235 |
| 9HTN Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2s 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1I4Q (3S)-3-(3,4-dihydro-2H-quinolin-1-yl)piperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
|
分辨率 1.92 Å R-free 0.235 |
| 9HTO Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2r 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1IW6 (3~{S})-3-indol-1-ylpiperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
|
分辨率 1.85 Å R-free 0.240 |
| 9HTO Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2r 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1IW6 (3~{S})-3-indol-1-ylpiperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
|
分辨率 1.85 Å R-free 0.240 |
| 9HTO Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2r 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1IW6 (3~{S})-3-indol-1-ylpiperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
|
分辨率 1.85 Å R-free 0.240 |
| 9HTP Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2p 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
|
分辨率 2.35 Å R-free 0.281 |
| 9HTP Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2p 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1IW5 (3~{S})-3-[methyl(phenyl)amino]piperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
|
分辨率 2.35 Å R-free 0.281 |
| 9HTP Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2p 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
|
分辨率 2.35 Å R-free 0.281 |
| 9HTQ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2u 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1IW4 (3~{S})-3-carbazol-9-ylpiperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 1.63 Å R-free 0.202 |
| 9HTQ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2u 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1IW4 (3~{S})-3-carbazol-9-ylpiperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 1.63 Å R-free 0.202 |
| 9HTQ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2u 提交 2024-12-19 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–124(124 aa)
|
未记录 | ZN ZINC ION × 1 A1IW4 (3~{S})-3-carbazol-9-ylpiperidine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
|
分辨率 1.63 Å R-free 0.202 |
共 61 个其他 PDB 条目、171 个 assembly。 打开独立比较页并筛选聚集状态
查看构建体与数据证据
| UniProt名称 | A4TVL0_9PROT |
| Isoform | — |
| PDB实体 | 1 |
| 链与序列区间 | 作者链 A; PDB构建体 2–125; UniProt 1–124 作者链 B; PDB构建体 2–125; UniProt 1–124 |